US EditionTransgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 Months with Individualized Cancer Vaccine TG4050 – DIR HONGKONG
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 months with Individualized Cancer Vaccine TG4050 – DIR HONGKONG
Strasbourg, France & Tokyo, Japan, June 2, 2025 – (JCN Newswire via SeaPRwire.com) – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TSE: 6701), a leader in IT, network and AI technologies, have presented new positive data on TG4050 in a rapid oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. These p…
Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 months with Individualized Cancer Vaccine TG4050 – EastMud
Strasbourg, France & Tokyo, Japan, June 2, 2025 – (JCN Newswire via SeaPRwire.com) – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TSE: 6701), a leader in IT, network and AI technologies, have presented new positive data on TG4050 in a rapid oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. These p…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
